Bladder cancer is the fifth most common malignancy in Europe and the United States that accounts for 65,084 deaths in the world annually. One of the greatest challenges in treating bladder cancer is the heterogeneity in patient responses given standard therapy regimens. I am currently working on a project that seeks to develop a mathematical model of the phenotypic properties of bladder cancer cells and their response to the standard of care Bacillus Calmette-Guerin (BCG) therapy. We are also examining specific genetic markers associated with immunogeneity and proliferation to determine if these genes have predictive ability in determining the efficacy of BCG therapy as well as developing alternative treatment scheduling of BCG through in silico model simulations.